Aratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) have received an average recommendation of “Hold” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $8.33.
A number of analysts have weighed in on the stock. BidaskClub lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Lake Street Capital cut their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, Jefferies Group LLC set a $8.00 price target on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Friday, August 4th.
ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/22/aratana-therapeutics-inc-petx-receives-consensus-recommendation-of-hold-from-analysts.html.
In other news, insider Ernst Heinen sold 10,000 shares of Aratana Therapeutics stock in a transaction on Friday, September 15th. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the transaction, the insider now owns 130,994 shares in the company, valued at $818,712.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Peter Steven St sold 50,000 shares of Aratana Therapeutics stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $6.24, for a total transaction of $312,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,000 shares of company stock worth $435,600. 5.20% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Ray Gerald L & Associates Ltd. lifted its holdings in Aratana Therapeutics by 0.8% in the second quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 200 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,200 shares during the period. American International Group Inc. lifted its holdings in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the period. ProShare Advisors LLC lifted its holdings in Aratana Therapeutics by 7.2% in the second quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 1,709 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in Aratana Therapeutics by 6.6% in the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,875 shares during the period. Institutional investors and hedge funds own 73.08% of the company’s stock.
Aratana Therapeutics (PETX) traded down 3.76% on Friday, reaching $6.14. The company’s stock had a trading volume of 434,711 shares. The firm’s market cap is $264.03 million. The firm’s 50 day moving average is $6.17 and its 200-day moving average is $6.26. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $9.15.
Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The firm had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. During the same quarter last year, the business posted $0.61 earnings per share. The company’s quarterly revenue was down 86.4% on a year-over-year basis. On average, equities research analysts anticipate that Aratana Therapeutics will post ($1.09) EPS for the current year.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.